CN114980914A - 低平均动脉压的1型肝肾综合征患者的治疗方法 - Google Patents

低平均动脉压的1型肝肾综合征患者的治疗方法 Download PDF

Info

Publication number
CN114980914A
CN114980914A CN202080073336.4A CN202080073336A CN114980914A CN 114980914 A CN114980914 A CN 114980914A CN 202080073336 A CN202080073336 A CN 202080073336A CN 114980914 A CN114980914 A CN 114980914A
Authority
CN
China
Prior art keywords
terlipressin
patient
administration
hrs
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080073336.4A
Other languages
English (en)
Chinese (zh)
Inventor
K·雅米尔
S·C·帕帕斯
P·托伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Hospital Products IP Unlimited Co
Original Assignee
Mallinckrodt Hospital Products IP Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Hospital Products IP Unlimited Co filed Critical Mallinckrodt Hospital Products IP Unlimited Co
Publication of CN114980914A publication Critical patent/CN114980914A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN202080073336.4A 2019-10-30 2020-10-29 低平均动脉压的1型肝肾综合征患者的治疗方法 Pending CN114980914A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
US62/928,152 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (1)

Publication Number Publication Date
CN114980914A true CN114980914A (zh) 2022-08-30

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080073336.4A Pending CN114980914A (zh) 2019-10-30 2020-10-29 低平均动脉压的1型肝肾综合征患者的治疗方法

Country Status (10)

Country Link
US (1) US20210128676A1 (https=)
EP (1) EP4051310A1 (https=)
JP (1) JP2023500654A (https=)
KR (1) KR20220092868A (https=)
CN (1) CN114980914A (https=)
AU (1) AU2020373408A1 (https=)
BR (1) BR112022006329A2 (https=)
CA (1) CA3159575A1 (https=)
MX (1) MX2022004157A (https=)
WO (1) WO2021084483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019089A (ko) * 2021-06-07 2024-02-14 말린크로트 파마슈티칼스 아일랜드 리미티드 간신장 증후군 1형 환자의 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206049A (zh) * 2014-10-24 2017-09-26 马林克罗特医疗产品知识产权公司 治疗患1型肝肾综合征的患者的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206049A (zh) * 2014-10-24 2017-09-26 马林克罗特医疗产品知识产权公司 治疗患1型肝肾综合征的患者的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARSHAL RAJEKAR ET AL.: "Terlipressin in hepatorenal syndrome: Evidence for present indications", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 26, no. 1, 1 January 2011 (2011-01-01), pages 109 - 114, XP055774439, DOI: 10.1111/j.1440-1746.2010.06583.x *
STEPHEN CHRIS PAPPAS ET AL.: "Terlipressin Treatment Is Associated with Significantly Increased Survival in Patients with Hepatorenal Syndrome Type 1 (HRS-1) and Low Baseline Mean Arterial Pressure (MAP), Independent of HRS Reversal", HEPATOLOGY, vol. 68, no. 1, 1 October 2018 (2018-10-01), pages 560, XP002802077 *

Also Published As

Publication number Publication date
CA3159575A1 (en) 2021-05-06
EP4051310A1 (en) 2022-09-07
US20210128676A1 (en) 2021-05-06
MX2022004157A (es) 2022-07-19
JP2023500654A (ja) 2023-01-10
KR20220092868A (ko) 2022-07-04
AU2020373408A1 (en) 2022-04-21
BR112022006329A2 (pt) 2022-08-16
WO2021084483A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
US20240366710A1 (en) Method of treating patients with hepatorenal syndrome type 1
CN111920939A (zh) 血管紧张素ii单独或以组合方式用于治疗低血压
JP5068253B2 (ja) 心臓血管疾患の治療
Jochberger et al. Course of vasopressin and copeptin plasma concentrations in a patient with severe septic shock
US6864237B2 (en) Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
CN114980914A (zh) 低平均动脉压的1型肝肾综合征患者的治疗方法
CN117425488A (zh) 治疗患有1型肝肾综合征的患者的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination